Scientists discover potent trigger of inflammatory disease

Institute scientists have revealed a potent inflammatory molecule released by dying cells triggers inflammation during necroptosis, a recently described form of cell death linked to inflammatory disease.

The discovery could lead to new and existing medicines that target the molecule being investigated as a way of treating inflammatory diseases, such as psoriasis and inflammatory bowel disease.

Dr Lisa Lindqvist, Dr Kate Lawlor, Dr James Vince and PhD student Ms Stephanie Conos led research that showed interleukin-1 beta (IL-1) triggers inflammation during necroptotic cell death.

Necroptosis is important for protecting us against infections, by sacrificing infected or diseased cells 'for the greater good'.

However, necroptosis can become inappropriately or excessively activated, triggering damaging inflammation that leads to inflammatory disease.

Dr Lindqvist said the discovery challenged a long-standing dogma that inflammation triggered by necroptosis was a byproduct of dead cell debris. "Our research has pinpointed that, during necroptosis, dying cells release IL-1, a potent inflammatory signal," Dr Lindqvist said.

"Now that we have discovered IL-1 is the 'root' of the inflammation associated with necroptosis, we speculate that targeting this molecule could be an effective way of treating inflammatory diseases."

Future treatments

The findings suggest that targeting IL-1 could suppress inflammation associated with multiple inflammatory diseases, including multiple sclerosis, ischemia-reperfusion injury, atherosclerosis, liver disease, pancreatitis, psoriasis, inflammatory bowel disease, and infectious diseases.

"Our research suggests that existing drugs that block IL-1 might be useful in treating these diseases," Dr Lindqvist said.

"We are also exploring how IL-1 is signalled to be secreted during necroptosis, so that we can create new drugs to stop its release and reduce inflammation to treat inflammatory diseases."

Source: Walter Reed Army Institute of Research

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer